{"transactions":[{"id":4631366,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Capped Value Appreciation Rights","published_at":"2026-10-05T23:42:24.000Z","date":"2026-10-01","kind":"exercise","planned":false,"acquired":false,"shares":92187,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"shares","element":"transactionShares","label":"F2","text":"On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These CVARs vest on the first date that each of (i) the Service Requirement, (ii) the Performance Requirement, and (iii) the Knock-in Requirement have been satisfied. The \"Service Requirement\" is satisfied as follows: (i) 25% of the CVARs vested on April 1, 2026; and (ii) the remaining 75% vests in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer or an affiliate on each such vesting date. The \"Performance Requirement\" is tied to the achievement of a specified clinical development activity at the Issuer, which requirement was met as of March 31, 2026. The \"Knock-in Requirement\" requires that the price of the Issuer's common stock at each applicable vesting date must be equal to or greater than $16.76 per share."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026."}],"balance_after":921875,"derivative":{"exercise_price":14.46,"expiration_date":"2030-04-01","underlying":"Common Stock","underlying_shares":92187},"source":{"system":"sec-edgar","filing":"0001764013-26-000110","document":"wk-form4_1791243741.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000110/wk-form4_1791243741.xml","form_type":"4"}},{"id":4631365,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-05T23:42:24.000Z","date":"2026-10-02","kind":"sale","planned":false,"acquired":false,"shares":3506,"price":34.11,"value":119589.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these CVARs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":257075,"source":{"system":"sec-edgar","filing":"0001764013-26-000110","document":"wk-form4_1791243741.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000110/wk-form4_1791243741.xml","form_type":"4"}},{"id":4631364,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-05T23:42:24.000Z","date":"2026-10-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":85886,"price":33.65,"value":2890063.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"shares","element":"transactionShares","label":"F2","text":"On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026."}],"balance_after":260581,"source":{"system":"sec-edgar","filing":"0001764013-26-000110","document":"wk-form4_1791243741.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000110/wk-form4_1791243741.xml","form_type":"4"}},{"id":4631363,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-05T23:42:24.000Z","date":"2026-10-01","kind":"exercise","planned":false,"acquired":true,"shares":92187,"price":14.46,"value":1333024.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"shares","element":"transactionShares","label":"F2","text":"On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026."}],"balance_after":346467,"source":{"system":"sec-edgar","filing":"0001764013-26-000110","document":"wk-form4_1791243741.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000110/wk-form4_1791243741.xml","form_type":"4"}},{"id":4629067,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-02T21:37:41.000Z","date":"2026-09-30","kind":"exercise","planned":true,"acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":3644834,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001635088-26-000108","document":"wk-form4_1790977058.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000163508826000108/wk-form4_1790977058.xml","form_type":"4"}},{"id":4629066,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-10-02T21:37:41.000Z","date":"2026-09-30","kind":"sale","planned":true,"acquired":false,"shares":200000,"price":36.62,"value":7324000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.49 to $36.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025."}],"balance_after":1599154,"source":{"system":"sec-edgar","filing":"0001635088-26-000108","document":"wk-form4_1790977058.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000163508826000108/wk-form4_1790977058.xml","form_type":"4"}},{"id":4629065,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-10-02T21:37:41.000Z","date":"2026-09-30","kind":"exercise","planned":true,"acquired":true,"shares":200000,"price":3.85,"value":770000.0,"ownership":{"direct":true},"balance_after":1799154,"source":{"system":"sec-edgar","filing":"0001635088-26-000108","document":"wk-form4_1790977058.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000163508826000108/wk-form4_1790977058.xml","form_type":"4"}},{"id":671257,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-02T01:00:30.000Z","date":"2026-08-28","kind":"exercise","planned":true,"acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":3844834,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001140361-26-035375","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036126035375/form4.xml","form_type":"4"}},{"id":671256,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-09-02T01:00:30.000Z","date":"2026-08-28","kind":"sale","planned":true,"acquired":false,"shares":33818,"price":36.44,"value":1232327.92,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.17 to $36.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025."}],"balance_after":1599154,"source":{"system":"sec-edgar","filing":"0001140361-26-035375","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036126035375/form4.xml","form_type":"4"}},{"id":671255,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-09-02T01:00:30.000Z","date":"2026-08-28","kind":"sale","planned":true,"acquired":false,"shares":166182,"price":35.63,"value":5921064.66,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.17 to $36.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025."}],"balance_after":1632972,"source":{"system":"sec-edgar","filing":"0001140361-26-035375","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036126035375/form4.xml","form_type":"4"}},{"id":671254,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-09-02T01:00:30.000Z","date":"2026-08-28","kind":"exercise","planned":true,"acquired":true,"shares":200000,"price":3.85,"value":770000.0,"ownership":{"direct":true},"balance_after":1799154,"source":{"system":"sec-edgar","filing":"0001140361-26-035375","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036126035375/form4.xml","form_type":"4"}},{"id":677465,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-08-25T01:00:09.000Z","date":"2026-08-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":13909,"price":36.84,"value":512407.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":1599154,"source":{"system":"sec-edgar","filing":"0001140361-26-034238","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036126034238/form4.xml","form_type":"4"}},{"id":701487,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-30T01:00:10.000Z","date":"2026-07-27","kind":"exercise","planned":true,"acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":4044834,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001140361-26-030107","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036126030107/form4.xml","form_type":"4"}},{"id":701486,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-07-30T01:00:10.000Z","date":"2026-07-27","kind":"sale","planned":true,"acquired":false,"shares":200000,"price":34.95,"value":6990000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.62 to $35.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."}],"balance_after":1613063,"source":{"system":"sec-edgar","filing":"0001140361-26-030107","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036126030107/form4.xml","form_type":"4"}},{"id":701485,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-07-30T01:00:10.000Z","date":"2026-07-27","kind":"exercise","planned":true,"acquired":true,"shares":200000,"price":3.85,"value":770000.0,"ownership":{"direct":true},"balance_after":1813063,"source":{"system":"sec-edgar","filing":"0001140361-26-030107","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036126030107/form4.xml","form_type":"4"}},{"id":715397,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Capped Value Appreciation Rights","published_at":"2026-07-06T21:01:25.000Z","date":"2026-07-01","kind":"exercise","planned":false,"acquired":false,"shares":92188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"shares","element":"transactionShares","label":"F2","text":"On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These CVARs vest on the first date that each of (i) the Service Requirement, (ii) the Performance Requirement, and (iii) the Knock-in Requirement have been satisfied. The \"Service Requirement\" is satisfied as follows: (i) 25% of the CVARs vested on April 1, 2026; and (ii) the remaining 75% vests in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer or an affiliate on each such vesting date. The \"Performance Requirement\" is tied to the achievement of a specified clinical development activity at the Issuer, which requirement was met as of March 31, 2026. The \"Knock-in Requirement\" requires that the price of the Issuer's common stock at each applicable vesting date must be equal to or greater than $16.76 per share."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026."}],"balance_after":1014062,"derivative":{"exercise_price":14.46,"expiration_date":"2030-04-01","underlying":"Common Stock","underlying_shares":92188},"source":{"system":"sec-edgar","filing":"0001764013-26-000077","document":"wk-form4_1783371682.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000077/wk-form4_1783371682.xml","form_type":"4"}},{"id":715396,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-06T21:01:25.000Z","date":"2026-07-02","kind":"sale","planned":false,"acquired":false,"shares":3092,"price":38.48,"value":118980.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these CVARs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":254280,"source":{"system":"sec-edgar","filing":"0001764013-26-000077","document":"wk-form4_1783371682.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000077/wk-form4_1783371682.xml","form_type":"4"}},{"id":715395,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-06T21:01:25.000Z","date":"2026-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":86629,"price":38.14,"value":3304030.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"shares","element":"transactionShares","label":"F2","text":"On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026."}],"balance_after":257372,"source":{"system":"sec-edgar","filing":"0001764013-26-000077","document":"wk-form4_1783371682.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000077/wk-form4_1783371682.xml","form_type":"4"}},{"id":715394,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-06T21:01:25.000Z","date":"2026-07-01","kind":"exercise","planned":false,"acquired":true,"shares":92188,"price":14.46,"value":1333038.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"shares","element":"transactionShares","label":"F2","text":"On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026."}],"balance_after":344001,"source":{"system":"sec-edgar","filing":"0001764013-26-000077","document":"wk-form4_1783371682.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000077/wk-form4_1783371682.xml","form_type":"4"}},{"id":725558,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-26T22:13:50.000Z","date":"2026-06-24","kind":"exercise","planned":true,"acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":4244834,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001635088-26-000071","document":"wk-form4_1782512028.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000163508826000071/wk-form4_1782512028.xml","form_type":"4"}},{"id":725557,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-06-26T22:13:50.000Z","date":"2026-06-24","kind":"sale","planned":true,"acquired":false,"shares":46234,"price":33.51,"value":1549301.34,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.23 to $33.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."}],"balance_after":1613063,"source":{"system":"sec-edgar","filing":"0001635088-26-000071","document":"wk-form4_1782512028.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000163508826000071/wk-form4_1782512028.xml","form_type":"4"}},{"id":725556,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-06-26T22:13:50.000Z","date":"2026-06-24","kind":"sale","planned":true,"acquired":false,"shares":153766,"price":33.05,"value":5081966.3,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.23 to $33.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."}],"balance_after":1659297,"source":{"system":"sec-edgar","filing":"0001635088-26-000071","document":"wk-form4_1782512028.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000163508826000071/wk-form4_1782512028.xml","form_type":"4"}},{"id":725555,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-06-26T22:13:50.000Z","date":"2026-06-24","kind":"exercise","planned":true,"acquired":true,"shares":200000,"price":3.85,"value":770000.0,"ownership":{"direct":true},"balance_after":1813063,"source":{"system":"sec-edgar","filing":"0001635088-26-000071","document":"wk-form4_1782512028.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000163508826000071/wk-form4_1782512028.xml","form_type":"4"}},{"id":766073,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-22T22:25:47.000Z","date":"2026-05-22","kind":"exercise","planned":true,"acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":4444834,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001635088-26-000065","document":"wk-form4_1779488744.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000163508826000065/wk-form4_1779488744.xml","form_type":"4"}},{"id":766072,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-05-22T22:25:47.000Z","date":"2026-05-22","kind":"sale","planned":true,"acquired":false,"shares":200000,"price":30.27,"value":6054000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."}],"balance_after":1613063,"source":{"system":"sec-edgar","filing":"0001635088-26-000065","document":"wk-form4_1779488744.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000163508826000065/wk-form4_1779488744.xml","form_type":"4"}},{"id":766071,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-05-22T22:25:47.000Z","date":"2026-05-22","kind":"exercise","planned":true,"acquired":true,"shares":200000,"price":3.85,"value":770000.0,"ownership":{"direct":true},"balance_after":1813063,"source":{"system":"sec-edgar","filing":"0001635088-26-000065","document":"wk-form4_1779488744.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000163508826000065/wk-form4_1779488744.xml","form_type":"4"}},{"id":766070,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-05-22T22:25:47.000Z","date":"2026-05-20","kind":"tax_withholding","planned":true,"acquired":false,"shares":34483,"price":32.41,"value":1117594.03,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":1613063,"source":{"system":"sec-edgar","filing":"0001635088-26-000065","document":"wk-form4_1779488744.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000163508826000065/wk-form4_1779488744.xml","form_type":"4"}},{"id":802928,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-22T22:27:47.000Z","date":"2026-04-20","kind":"exercise","planned":true,"acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":4644834,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001635088-26-000044","document":"wk-form4_1776896865.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000163508826000044/wk-form4_1776896865.xml","form_type":"4"}},{"id":802927,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-04-22T22:27:47.000Z","date":"2026-04-20","kind":"sale","planned":true,"acquired":false,"shares":200000,"price":29.59,"value":5918000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.33 to $29.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."}],"balance_after":1647546,"source":{"system":"sec-edgar","filing":"0001635088-26-000044","document":"wk-form4_1776896865.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000163508826000044/wk-form4_1776896865.xml","form_type":"4"}},{"id":802926,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-04-22T22:27:47.000Z","date":"2026-04-20","kind":"exercise","planned":true,"acquired":true,"shares":200000,"price":3.85,"value":770000.0,"ownership":{"direct":true},"balance_after":1847546,"source":{"system":"sec-edgar","filing":"0001635088-26-000044","document":"wk-form4_1776896865.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000163508826000044/wk-form4_1776896865.xml","form_type":"4"}},{"id":811532,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-09T20:13:44.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":336043,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options were granted pursuant to the Plan. The shares underlying the options will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in thirty-six (36) successive substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":336043,"derivative":{"exercise_price":24.61,"expiration_date":"2036-04-07","underlying":"Common Stock","underlying_shares":336043},"source":{"system":"sec-edgar","filing":"0001764013-26-000034","document":"wk-form4_1775765620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000034/wk-form4_1775765620.xml","form_type":"4"}},{"id":811531,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-09T20:13:44.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":232252,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units (\"RSUs\") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the \"Plan\"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":251813,"source":{"system":"sec-edgar","filing":"0001764013-26-000034","document":"wk-form4_1775765620.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000034/wk-form4_1775765620.xml","form_type":"4"}},{"id":816574,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Capped Value Appreciation Rights","published_at":"2026-04-03T20:33:01.000Z","date":"2026-04-01","kind":"exercise","planned":false,"acquired":false,"shares":368750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"shares","element":"transactionShares","label":"F2","text":"On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These CVARs vest on the first date that each of (i) the Service Requirement, (ii) the Performance Requirement, and (iii) the Knock-in Requirement have been satisfied. The \"Service Requirement\" is satisfied as follows: (i) 25% of the CVARs vested on April 1, 2026; and (ii) the remaining 75% vests in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer or an affiliate on each such vesting date. The \"Performance Requirement\" is tied to the achievement of a specified clinical development activity at the Issuer, which requirement was met as of March 31, 2026. The \"Knock-in Requirement\" requires that the price of the Issuer's common stock at each applicable vesting date must be equal to or greater than $16.76 per share."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026."}],"balance_after":1106250,"derivative":{"exercise_price":14.46,"expiration_date":"2030-04-01","underlying":"Common Stock","underlying_shares":368750},"source":{"system":"sec-edgar","filing":"0001764013-26-000024","document":"wk-form4_1775248378.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000024/wk-form4_1775248378.xml","form_type":"4"}},{"id":816573,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-03T20:33:01.000Z","date":"2026-04-02","kind":"sale","planned":false,"acquired":false,"shares":1409,"price":24.6,"value":34661.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these CVARs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.51 - $24.70 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":19561,"source":{"system":"sec-edgar","filing":"0001764013-26-000024","document":"wk-form4_1775248378.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000024/wk-form4_1775248378.xml","form_type":"4"}},{"id":816572,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-03T20:33:01.000Z","date":"2026-04-02","kind":"sale","planned":false,"acquired":false,"shares":12820,"price":24.04,"value":308192.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these CVARs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.50 - $24.49 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":20970,"source":{"system":"sec-edgar","filing":"0001764013-26-000024","document":"wk-form4_1775248378.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000024/wk-form4_1775248378.xml","form_type":"4"}},{"id":816571,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-03T20:33:01.000Z","date":"2026-04-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":334960,"price":25.1,"value":8407496.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"shares","element":"transactionShares","label":"F2","text":"On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026."}],"balance_after":33790,"source":{"system":"sec-edgar","filing":"0001764013-26-000024","document":"wk-form4_1775248378.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000024/wk-form4_1775248378.xml","form_type":"4"}},{"id":816570,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-03T20:33:01.000Z","date":"2026-04-01","kind":"exercise","planned":false,"acquired":true,"shares":368750,"price":14.46,"value":5332125.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"shares","element":"transactionShares","label":"F2","text":"On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026."}],"balance_after":368750,"source":{"system":"sec-edgar","filing":"0001764013-26-000024","document":"wk-form4_1775248378.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000024/wk-form4_1775248378.xml","form_type":"4"}},{"id":833565,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-19T22:36:44.000Z","date":"2026-03-17","kind":"exercise","planned":true,"acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation)."}],"balance_after":4844834,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001635088-26-000026","document":"wk-form4_1773959801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000163508826000026/wk-form4_1773959801.xml","form_type":"4"}},{"id":833564,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-03-19T22:36:44.000Z","date":"2026-03-17","kind":"sale","planned":true,"acquired":false,"shares":200000,"price":28.24,"value":5648000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.04 to $28.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."}],"balance_after":1647546,"source":{"system":"sec-edgar","filing":"0001635088-26-000026","document":"wk-form4_1773959801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000163508826000026/wk-form4_1773959801.xml","form_type":"4"}},{"id":833563,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-03-19T22:36:44.000Z","date":"2026-03-17","kind":"exercise","planned":true,"acquired":true,"shares":200000,"price":3.85,"value":770000.0,"ownership":{"direct":true},"balance_after":1847546,"source":{"system":"sec-edgar","filing":"0001635088-26-000026","document":"wk-form4_1773959801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000163508826000026/wk-form4_1773959801.xml","form_type":"4"}},{"id":885104,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-02-24T23:43:18.000Z","date":"2026-02-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":7051,"price":27.15,"value":191434.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":1647546,"source":{"system":"sec-edgar","filing":"0001635088-26-000022","document":"wk-form4_1771976596.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000163508826000022/wk-form4_1771976596.xml","form_type":"4"}},{"id":897015,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-18T22:57:13.000Z","date":"2026-02-13","kind":"exercise","planned":true,"acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation)."}],"balance_after":5044834,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001635088-26-000017","document":"wk-form4_1771455431.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000163508826000017/wk-form4_1771455431.xml","form_type":"4"}},{"id":897014,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-02-18T22:57:13.000Z","date":"2026-02-13","kind":"sale","planned":true,"acquired":false,"shares":200000,"price":26.49,"value":5298000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.35 to $26.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."}],"balance_after":1654597,"source":{"system":"sec-edgar","filing":"0001635088-26-000017","document":"wk-form4_1771455431.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000163508826000017/wk-form4_1771455431.xml","form_type":"4"}},{"id":897013,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-02-18T22:57:13.000Z","date":"2026-02-13","kind":"exercise","planned":true,"acquired":true,"shares":200000,"price":3.85,"value":770000.0,"ownership":{"direct":true},"balance_after":1854597,"source":{"system":"sec-edgar","filing":"0001635088-26-000017","document":"wk-form4_1771455431.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000163508826000017/wk-form4_1771455431.xml","form_type":"4"}},{"id":939267,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-15T02:00:31.000Z","date":"2026-01-12","kind":"exercise","planned":true,"acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation)."}],"balance_after":5244834,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001140361-26-001239","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036126001239/form4.xml","form_type":"4"}},{"id":939266,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-01-15T02:00:31.000Z","date":"2026-01-12","kind":"sale","planned":true,"acquired":false,"shares":200000,"price":21.92,"value":4384000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.59 to $22.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."}],"balance_after":1654597,"source":{"system":"sec-edgar","filing":"0001140361-26-001239","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036126001239/form4.xml","form_type":"4"}},{"id":939265,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-01-15T02:00:31.000Z","date":"2026-01-12","kind":"exercise","planned":true,"acquired":true,"shares":200000,"price":3.85,"value":770000.0,"ownership":{"direct":true},"balance_after":1854597,"source":{"system":"sec-edgar","filing":"0001140361-26-001239","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036126001239/form4.xml","form_type":"4"}},{"id":958254,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-30T02:00:20.000Z","date":"2025-12-24","kind":"exercise","planned":false,"acquired":false,"shares":117848,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation)."}],"balance_after":5444834,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Stock","underlying_shares":117848},"source":{"system":"sec-edgar","filing":"0001140361-25-046786","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125046786/form4.xml","form_type":"4"}},{"id":958253,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-30T02:00:20.000Z","date":"2025-12-23","kind":"exercise","planned":false,"acquired":false,"shares":313841,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation)."}],"balance_after":5562682,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Stock","underlying_shares":313841},"source":{"system":"sec-edgar","filing":"0001140361-25-046786","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125046786/form4.xml","form_type":"4"}},{"id":958252,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-12-30T02:00:20.000Z","date":"2025-12-24","kind":"sale","planned":false,"acquired":false,"shares":75000,"price":22.53,"value":1689750.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an exercise and hold transaction, with a sale of Common Shares only to cover applicable withholding taxes and the exercise price of the stock options exercised."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These Common Shares were sold in multiple transactions at prices ranging from $22.50 to $22.63, inclusive."}],"balance_after":1654597,"source":{"system":"sec-edgar","filing":"0001140361-25-046786","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125046786/form4.xml","form_type":"4"}},{"id":958251,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-12-30T02:00:20.000Z","date":"2025-12-24","kind":"exercise","planned":false,"acquired":true,"shares":117848,"price":3.85,"value":453714.8,"ownership":{"direct":true},"balance_after":1729597,"source":{"system":"sec-edgar","filing":"0001140361-25-046786","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125046786/form4.xml","form_type":"4"}},{"id":958250,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-12-30T02:00:20.000Z","date":"2025-12-23","kind":"sale","planned":false,"acquired":false,"shares":200000,"price":22.45,"value":4490000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an exercise and hold transaction, with a sale of Common Shares only to cover applicable withholding taxes and the exercise price of the stock options exercised."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These Common Shares were sold in multiple transactions at prices ranging from $22.25 to $22.64, inclusive."}],"balance_after":1611749,"source":{"system":"sec-edgar","filing":"0001140361-25-046786","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125046786/form4.xml","form_type":"4"}},{"id":958249,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-12-30T02:00:20.000Z","date":"2025-12-23","kind":"exercise","planned":false,"acquired":true,"shares":313841,"price":3.85,"value":1208287.85,"ownership":{"direct":true},"balance_after":1811749,"source":{"system":"sec-edgar","filing":"0001140361-25-046786","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125046786/form4.xml","form_type":"4"}},{"id":972708,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-12T02:00:22.000Z","date":"2025-12-09","kind":"exercise","planned":true,"acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation)."}],"balance_after":5876523,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001140361-25-045279","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125045279/form4.xml","form_type":"4"}},{"id":972707,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-12-12T02:00:22.000Z","date":"2025-12-09","kind":"sale","planned":true,"acquired":false,"shares":200000,"price":20.85,"value":4170000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025."}],"balance_after":1497908,"source":{"system":"sec-edgar","filing":"0001140361-25-045279","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125045279/form4.xml","form_type":"4"}},{"id":972706,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-12-12T02:00:22.000Z","date":"2025-12-09","kind":"exercise","planned":true,"acquired":true,"shares":200000,"price":3.85,"value":770000.0,"ownership":{"direct":true},"balance_after":1697908,"source":{"system":"sec-edgar","filing":"0001140361-25-045279","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125045279/form4.xml","form_type":"4"}},{"id":990205,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-11-25T02:00:13.000Z","date":"2025-11-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":7051,"price":20.27,"value":142923.77,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":1497908,"source":{"system":"sec-edgar","filing":"0001140361-25-043201","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125043201/form4.xml","form_type":"4"}},{"id":1004929,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-08T02:00:42.000Z","date":"2025-11-07","kind":"exercise","planned":true,"acquired":false,"shares":200000,"price":20.22,"value":4044000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation)."}],"balance_after":6076523,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001140361-25-041214","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125041214/form4.xml","form_type":"4"}},{"id":1004928,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-11-08T02:00:42.000Z","date":"2025-11-07","kind":"sale","planned":true,"acquired":false,"shares":200000,"price":20.22,"value":4044000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025."}],"balance_after":1504959,"source":{"system":"sec-edgar","filing":"0001140361-25-041214","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125041214/form4.xml","form_type":"4"}},{"id":1004927,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-11-08T02:00:42.000Z","date":"2025-11-07","kind":"exercise","planned":true,"acquired":true,"shares":200000,"price":3.85,"value":770000.0,"ownership":{"direct":true},"balance_after":1704959,"source":{"system":"sec-edgar","filing":"0001140361-25-041214","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125041214/form4.xml","form_type":"4"}},{"id":1016838,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-18T01:00:12.000Z","date":"2025-10-17","kind":"exercise","planned":true,"acquired":false,"shares":118418,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":15.85,"expiration_date":"2026-03-31","underlying":"Common Stock","underlying_shares":118418},"source":{"system":"sec-edgar","filing":"0001140361-25-038545","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125038545/form4.xml","form_type":"4"}},{"id":1016837,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-18T01:00:12.000Z","date":"2025-10-16","kind":"exercise","planned":true,"acquired":false,"shares":318282,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options are fully vested."}],"balance_after":118418,"derivative":{"exercise_price":15.85,"expiration_date":"2026-03-31","underlying":"Common Stock","underlying_shares":318282},"source":{"system":"sec-edgar","filing":"0001140361-25-038545","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125038545/form4.xml","form_type":"4"}},{"id":1016836,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-18T01:00:12.000Z","date":"2025-10-15","kind":"exercise","planned":true,"acquired":false,"shares":414683,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options are fully vested."}],"balance_after":436700,"derivative":{"exercise_price":15.85,"expiration_date":"2026-03-31","underlying":"Common Stock","underlying_shares":414683},"source":{"system":"sec-edgar","filing":"0001140361-25-038545","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125038545/form4.xml","form_type":"4"}},{"id":1016835,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-10-18T01:00:12.000Z","date":"2025-10-17","kind":"sale","planned":true,"acquired":false,"shares":118418,"price":17.06,"value":2020211.08,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025."}],"balance_after":1504959,"source":{"system":"sec-edgar","filing":"0001140361-25-038545","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125038545/form4.xml","form_type":"4"}},{"id":1016834,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-10-18T01:00:12.000Z","date":"2025-10-17","kind":"exercise","planned":true,"acquired":true,"shares":118418,"price":15.85,"value":1876925.3,"ownership":{"direct":true},"balance_after":1623377,"source":{"system":"sec-edgar","filing":"0001140361-25-038545","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125038545/form4.xml","form_type":"4"}},{"id":1016833,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-10-18T01:00:12.000Z","date":"2025-10-16","kind":"sale","planned":true,"acquired":false,"shares":318282,"price":17.05,"value":5426708.1,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025."}],"balance_after":1504959,"source":{"system":"sec-edgar","filing":"0001140361-25-038545","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125038545/form4.xml","form_type":"4"}},{"id":1016832,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-10-18T01:00:12.000Z","date":"2025-10-16","kind":"exercise","planned":true,"acquired":true,"shares":318282,"price":15.85,"value":5044769.7,"ownership":{"direct":true},"balance_after":1823241,"source":{"system":"sec-edgar","filing":"0001140361-25-038545","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125038545/form4.xml","form_type":"4"}},{"id":1016831,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-10-18T01:00:12.000Z","date":"2025-10-15","kind":"sale","planned":true,"acquired":false,"shares":414683,"price":16.93,"value":7020583.19,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025."}],"balance_after":1504959,"source":{"system":"sec-edgar","filing":"0001140361-25-038545","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125038545/form4.xml","form_type":"4"}},{"id":1016830,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-10-18T01:00:12.000Z","date":"2025-10-15","kind":"exercise","planned":true,"acquired":true,"shares":414683,"price":15.85,"value":6572725.55,"ownership":{"direct":true},"balance_after":1919642,"source":{"system":"sec-edgar","filing":"0001140361-25-038545","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125038545/form4.xml","form_type":"4"}},{"id":1019320,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-15T01:00:10.000Z","date":"2025-10-13","kind":"exercise","planned":true,"acquired":false,"shares":20727,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options are fully vested."}],"balance_after":851383,"derivative":{"exercise_price":15.85,"expiration_date":"2026-03-31","underlying":"Common Stock","underlying_shares":20727},"source":{"system":"sec-edgar","filing":"0001140361-25-038126","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125038126/form4.xml","form_type":"4"}},{"id":1019319,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-15T01:00:10.000Z","date":"2025-10-09","kind":"exercise","planned":true,"acquired":false,"shares":104940,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options are fully vested."}],"balance_after":872110,"derivative":{"exercise_price":15.85,"expiration_date":"2026-03-31","underlying":"Common Stock","underlying_shares":104940},"source":{"system":"sec-edgar","filing":"0001140361-25-038126","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125038126/form4.xml","form_type":"4"}},{"id":1019318,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-10-15T01:00:10.000Z","date":"2025-10-13","kind":"sale","planned":true,"acquired":false,"shares":20727,"price":16.25,"value":336813.75,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025."}],"balance_after":1504959,"source":{"system":"sec-edgar","filing":"0001140361-25-038126","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125038126/form4.xml","form_type":"4"}},{"id":1019317,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-10-15T01:00:10.000Z","date":"2025-10-13","kind":"exercise","planned":true,"acquired":true,"shares":20727,"price":15.85,"value":328522.95,"ownership":{"direct":true},"balance_after":1525686,"source":{"system":"sec-edgar","filing":"0001140361-25-038126","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125038126/form4.xml","form_type":"4"}},{"id":1019316,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-10-15T01:00:10.000Z","date":"2025-10-09","kind":"sale","planned":true,"acquired":false,"shares":104940,"price":16.3,"value":1710522.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025."}],"balance_after":1504959,"source":{"system":"sec-edgar","filing":"0001140361-25-038126","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125038126/form4.xml","form_type":"4"}},{"id":1019315,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-10-15T01:00:10.000Z","date":"2025-10-09","kind":"exercise","planned":true,"acquired":true,"shares":104940,"price":15.85,"value":1663299.0,"ownership":{"direct":true},"balance_after":1609899,"source":{"system":"sec-edgar","filing":"0001140361-25-038126","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125038126/form4.xml","form_type":"4"}},{"id":1021562,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-09T01:00:39.000Z","date":"2025-10-08","kind":"exercise","planned":true,"acquired":false,"shares":128295,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Award of stock options to purchase Common Shares with a vesting commencement date of October 16, 2017. These options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.45,"expiration_date":"2027-11-20","underlying":"Common Stock","underlying_shares":128295},"source":{"system":"sec-edgar","filing":"0001140361-25-037740","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125037740/form4.xml","form_type":"4"}},{"id":1021561,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-09T01:00:39.000Z","date":"2025-10-08","kind":"exercise","planned":true,"acquired":false,"shares":10307,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options are fully vested."}],"balance_after":977050,"derivative":{"exercise_price":15.85,"expiration_date":"2026-03-31","underlying":"Common Stock","underlying_shares":10307},"source":{"system":"sec-edgar","filing":"0001140361-25-037740","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125037740/form4.xml","form_type":"4"}},{"id":1021560,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-09T01:00:39.000Z","date":"2025-10-07","kind":"exercise","planned":true,"acquired":false,"shares":180859,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation)."}],"balance_after":6276523,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Stock","underlying_shares":180859},"source":{"system":"sec-edgar","filing":"0001140361-25-037740","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125037740/form4.xml","form_type":"4"}},{"id":1021559,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-09T01:00:39.000Z","date":"2025-10-07","kind":"exercise","planned":true,"acquired":false,"shares":107131,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Award of stock options to purchase Common Shares with a vesting commencement date of October 16, 2017. These options are fully vested."}],"balance_after":128295,"derivative":{"exercise_price":7.45,"expiration_date":"2027-11-20","underlying":"Common Stock","underlying_shares":107131},"source":{"system":"sec-edgar","filing":"0001140361-25-037740","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125037740/form4.xml","form_type":"4"}},{"id":1021558,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-09T01:00:39.000Z","date":"2025-10-07","kind":"exercise","planned":true,"acquired":false,"shares":67171,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options are fully vested."}],"balance_after":987357,"derivative":{"exercise_price":15.85,"expiration_date":"2026-03-31","underlying":"Common Stock","underlying_shares":67171},"source":{"system":"sec-edgar","filing":"0001140361-25-037740","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125037740/form4.xml","form_type":"4"}},{"id":1021557,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-09T01:00:39.000Z","date":"2025-10-06","kind":"exercise","planned":true,"acquired":false,"shares":19141,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation)."}],"balance_after":6457382,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Stock","underlying_shares":19141},"source":{"system":"sec-edgar","filing":"0001140361-25-037740","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125037740/form4.xml","form_type":"4"}},{"id":1021556,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-09T01:00:39.000Z","date":"2025-10-06","kind":"exercise","planned":true,"acquired":false,"shares":24900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Award of stock options to purchase Common Shares with a vesting commencement date of October 16, 2017. These options are fully vested."}],"balance_after":235426,"derivative":{"exercise_price":7.45,"expiration_date":"2027-11-20","underlying":"Common Stock","underlying_shares":24900},"source":{"system":"sec-edgar","filing":"0001140361-25-037740","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125037740/form4.xml","form_type":"4"}},{"id":1021555,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-09T01:00:39.000Z","date":"2025-10-06","kind":"exercise","planned":true,"acquired":false,"shares":127355,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options are fully vested."}],"balance_after":1054528,"derivative":{"exercise_price":15.85,"expiration_date":"2026-03-31","underlying":"Common Stock","underlying_shares":127355},"source":{"system":"sec-edgar","filing":"0001140361-25-037740","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125037740/form4.xml","form_type":"4"}},{"id":1021554,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-10-09T01:00:39.000Z","date":"2025-10-08","kind":"sale","planned":true,"acquired":false,"shares":138602,"price":16.2,"value":2245352.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025."}],"balance_after":1504959,"source":{"system":"sec-edgar","filing":"0001140361-25-037740","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125037740/form4.xml","form_type":"4"}},{"id":1021553,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-10-09T01:00:39.000Z","date":"2025-10-08","kind":"exercise","planned":true,"acquired":true,"shares":128295,"price":7.45,"value":955797.75,"ownership":{"direct":true},"balance_after":1643561,"source":{"system":"sec-edgar","filing":"0001140361-25-037740","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125037740/form4.xml","form_type":"4"}},{"id":1021552,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-10-09T01:00:39.000Z","date":"2025-10-08","kind":"exercise","planned":true,"acquired":true,"shares":10307,"price":15.85,"value":163365.95,"ownership":{"direct":true},"balance_after":1515266,"source":{"system":"sec-edgar","filing":"0001140361-25-037740","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125037740/form4.xml","form_type":"4"}},{"id":1021551,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-10-09T01:00:39.000Z","date":"2025-10-07","kind":"sale","planned":true,"acquired":false,"shares":355161,"price":16.15,"value":5735850.15,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025."}],"balance_after":1504959,"source":{"system":"sec-edgar","filing":"0001140361-25-037740","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125037740/form4.xml","form_type":"4"}},{"id":1021550,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-10-09T01:00:39.000Z","date":"2025-10-07","kind":"exercise","planned":true,"acquired":true,"shares":180859,"price":3.85,"value":696307.15,"ownership":{"direct":true},"balance_after":1860120,"source":{"system":"sec-edgar","filing":"0001140361-25-037740","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125037740/form4.xml","form_type":"4"}},{"id":1021549,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-10-09T01:00:39.000Z","date":"2025-10-07","kind":"exercise","planned":true,"acquired":true,"shares":107131,"price":7.45,"value":798125.95,"ownership":{"direct":true},"balance_after":1679261,"source":{"system":"sec-edgar","filing":"0001140361-25-037740","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125037740/form4.xml","form_type":"4"}},{"id":1021548,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-10-09T01:00:39.000Z","date":"2025-10-07","kind":"exercise","planned":true,"acquired":true,"shares":67171,"price":15.85,"value":1064660.35,"ownership":{"direct":true},"balance_after":1572130,"source":{"system":"sec-edgar","filing":"0001140361-25-037740","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125037740/form4.xml","form_type":"4"}},{"id":1021547,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-10-09T01:00:39.000Z","date":"2025-10-06","kind":"sale","planned":true,"acquired":false,"shares":171396,"price":16.34,"value":2800610.64,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025."}],"balance_after":1504959,"source":{"system":"sec-edgar","filing":"0001140361-25-037740","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125037740/form4.xml","form_type":"4"}},{"id":1021546,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-10-09T01:00:39.000Z","date":"2025-10-06","kind":"exercise","planned":true,"acquired":true,"shares":19141,"price":3.85,"value":73692.85,"ownership":{"direct":true},"balance_after":1676355,"source":{"system":"sec-edgar","filing":"0001140361-25-037740","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125037740/form4.xml","form_type":"4"}},{"id":1021545,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-10-09T01:00:39.000Z","date":"2025-10-06","kind":"exercise","planned":true,"acquired":true,"shares":24900,"price":7.45,"value":185505.0,"ownership":{"direct":true},"balance_after":1657214,"source":{"system":"sec-edgar","filing":"0001140361-25-037740","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125037740/form4.xml","form_type":"4"}},{"id":1021544,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-10-09T01:00:39.000Z","date":"2025-10-06","kind":"exercise","planned":true,"acquired":true,"shares":127355,"price":15.85,"value":2018576.75,"ownership":{"direct":true},"balance_after":1632314,"source":{"system":"sec-edgar","filing":"0001140361-25-037740","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125037740/form4.xml","form_type":"4"}},{"id":1033805,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-24T01:00:20.000Z","date":"2025-09-22","kind":"exercise","planned":true,"acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation)."}],"balance_after":6476523,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001140361-25-035890","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125035890/form4.xml","form_type":"4"}},{"id":1033804,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-24T01:00:20.000Z","date":"2025-09-22","kind":"exercise","planned":true,"acquired":false,"shares":462374,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation)."}],"balance_after":6576523,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Stock","underlying_shares":462374},"source":{"system":"sec-edgar","filing":"0001140361-25-035890","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125035890/form4.xml","form_type":"4"}},{"id":1033803,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-24T01:00:20.000Z","date":"2025-09-19","kind":"exercise","planned":true,"acquired":false,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation)."}],"balance_after":7038897,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001140361-25-035890","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125035890/form4.xml","form_type":"4"}},{"id":1033802,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-09-24T01:00:20.000Z","date":"2025-09-23","kind":"sale","planned":true,"acquired":false,"shares":611000,"price":14.83,"value":9061130.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."}],"balance_after":1504959,"source":{"system":"sec-edgar","filing":"0001140361-25-035890","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125035890/form4.xml","form_type":"4"}},{"id":1033801,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-09-24T01:00:20.000Z","date":"2025-09-22","kind":"sale","planned":true,"acquired":false,"shares":100000,"price":15.01,"value":1501000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 25, 2024."}],"balance_after":2115959,"source":{"system":"sec-edgar","filing":"0001140361-25-035890","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125035890/form4.xml","form_type":"4"}},{"id":1033800,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2025-09-24T01:00:20.000Z","date":"2025-09-22","kind":"sale","planned":true,"acquired":false,"shares":316182,"price":14.99,"value":4739568.18,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."}],"balance_after":2215959,"source":{"system":"sec-edgar","filing":"0001140361-25-035890","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036125035890/form4.xml","form_type":"4"}}],"next_cursor":"2025-09-24T01:00:20.000000Z,1033800"}